In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

EchoGo® Amyloidosis is the first FDA-cleared AI screening tool for cardiac amyloidosis using an echocardiogram and has received Breakthrough Device designation from the FDA.

Explore how AI transforms cardiac amyloidosis detection with remarkable accuracy—keep reading to see its clinical potential.

Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical.EchoGo® Amyloidosis is the ...

Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical.EchoGo® Amyloidosis is the ...

A routine, low-cost heart test may be on the verge of a transformative upgrade thanks to artificial intelligence. With ...

A seventh-generation Azurion Biplane Cath Lab system, an interventional imaging platform that will significantly enhance cardiac care, neurovascular interventions, and complex endovascular ...

Start With the Why Leaving the trusted environment of a primary care office can be daunting for patients, particularly for those who haven't had cardiac testing before.

Left Atrial Veno-Arterial ECMO (LAVA-ECMO) in Cardiogenic Shock as a Bridge to Surgical or Transcatheter Therapies: A Single-Center Experience Receive the the latest news, research, and presentations ...

Cardiac amyloidosis has a wide spectrum of clinical manifestations but the most frequent presentation is heart failure. Differential diagnoses from other restrictive cardiomyopathies is important.